Clinical Trials Logo

Clinical Trial Summary

Cocaine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce cocaine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of cocaine and alternative reinforcers. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for cocaine use disorders. We hypothesize that buspirone will attenuate the reinforcing effects of cocaine and increase the reinforcing effects of alternative reinforcers.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01639157
Study type Interventional
Source University of Kentucky
Contact
Status Completed
Phase N/A
Start date September 2012
Completion date December 2014

See also
  Status Clinical Trial Phase
Completed NCT00759473 - D-Cycloserine Facilitation of Cocaine - Cue Extinction Phase 2
Completed NCT00780442 - D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals Phase 2
Completed NCT00178776 - A Transtheoretical Model Group Therapy for Cocaine Phase 1
Recruiting NCT02680288 - Lorcaserin Intra Venous Cocaine Effects Phase 1/Phase 2
Completed NCT02909101 - Project IMPACT: Improving Memory Performance by Applying Cognitive Training N/A
Completed NCT01739192 - A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence Early Phase 1
Completed NCT01495195 - Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior Phase 2
Completed NCT02373124 - Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial Phase 1/Phase 2